Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apatinib + fluorouracil + platinum
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Apatinib is a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2) to inhibit tumor angiogenesis. In this specific therapeutic regimen, it is combined with fluorouracil (an antimetabolite) and platinum-based chemotherapy (DNA cross-linking agents) to treat recurrent or metastatic esophageal squamous cell carcinoma. This combination therapy is designed to provide synergistic effects by inhibiting tumor blood vessel growth while simultaneously inducing cytotoxic damage to cancer cells. The regimen is currently being evaluated in Phase 2 clinical trials sponsored by The First Affiliated Hospital of Anhui Medical University, with apatinib originally developed by Jiangsu Hengrui Medicine.
- Brand names
- Aitan
- Other names
- Rivoceranib5-fluorouracilcisplatincarboplatin
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on apatinib + fluorouracil + platinum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apatinib + fluorouracil + platinum.